Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Table 6 Investigational combinations of VEGFR-associated multi-targeted TKIs and anti-PD-1/PD-L1 antibodies

Combination therapy	Application	Clinical trial	Publications
Lenvatinib + pembrolizumab	Unresectable HCC	KEYNOTE-524/Study116 (Ib, NCT03006926) LEAP-002 (III, NCT03713593)	[112]
Lenvatinib + pembrolizumab	Solid tumors	Ib/II, NCT02501096	Ongoing [221]
Apatinib + camrelizumab	2L SCLC	PASSION (II, NCT03417895)	[222]
Axitinib + pembrolizumab	1L RCC	KEYNOTE426 (III, NCT02853331)	[214]
Axitinib + avelumab	1L RCC	JAVELIN Renal 101 trial (III, NCT02684006)	[215, 223]
Axitinib + toripalimab	1L metastatic mucosal melanoma	Ib (NCT03086174)	[224]
Regorafenib + avelumab	Non-MSI-H mCRC	I/II (NCT03475953)	[225]
Surufatinib + toripalimab	Solid tumors	I (NCT03879057)	[226]

HCC hepatocellular carcinoma, SCLC small cell lung cancer, RCC renal cell carcinoma, Non-MSI-H non-microsatellite instability-high
Data source: www.fda.gov, and www.clinicaltrials.gov (cutoff date: 19 July 2020)

ISSN: 1756-8722